Literature DB >> 17287054

Active immunization against Alzheimer's beta-amyloid peptide using phage display technology.

Beka Solomon1.   

Abstract

Beta-amyloid peptide (AbetaP) aggregation, an essentially early event in Alzheimer's disease (AD) pathogenesis, became a target for therapeutics. We developed an immunization procedure, using as antigen the EFRH peptide located at the N-terminal region of AbetaP displayed on the filamentous phage, to raise anti-beta-amyloid peptide antibodies. Data demonstrated that a bacteriophage displaying different numbers of copies of self-epitope modulates the intensity of the immuno response. This immunization procedure led to improvement in cognitive functions and alleviated amyloid pathology in a transgenic mouse (Tg) model of AD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17287054     DOI: 10.1016/j.vaccine.2007.01.069

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

Review 1.  Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications.

Authors:  Justyna Bazan; Ireneusz Całkosiński; Andrzej Gamian
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

2.  Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-14       Impact factor: 17.088

3.  In vivo characteristics of targeted drug-carrying filamentous bacteriophage nanomedicines.

Authors:  Lilach Vaks; Itai Benhar
Journal:  J Nanobiotechnology       Date:  2011-12-20       Impact factor: 10.435

4.  Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Michael Mante; Harald Weninger; Christina Patrick; Anthony Adame; Sabine Schmidhuber; Radmila Santic; Achim Schneeberger; Walter Schmidt; Frank Mattner; Eliezer Masliah
Journal:  Mol Neurodegener       Date:  2015-03-19       Impact factor: 14.195

Review 5.  Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines.

Authors:  Kyriakos A Hassapis; Dora C Stylianou; Leondios G Kostrikis
Journal:  Viruses       Date:  2014-12-17       Impact factor: 5.048

6.  The development of inovirus-associated vector vaccines using phage-display technologies.

Authors:  Zachariah Stern; Dora C Stylianou; Leondios G Kostrikis
Journal:  Expert Rev Vaccines       Date:  2019-09-08       Impact factor: 5.217

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.